Tysabri (natalizumab) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The tysabri (natalizumab) market size has grown strongly in recent years. It will grow from $2.66 million in 2025 to $2.87 million in 2026 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to increasing multiple sclerosis prevalence, approval of natalizumab therapy, neurologist adoption, unmet need in aggressive ms, infusion center expansion.

The tysabri (natalizumab) market size is expected to see strong growth in the next few years. It will grow to $3.87 million in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to growth in ms diagnosis rates, improved infusion infrastructure, enhanced risk mitigation programs, rising specialty neurology services, long-term clinical outcome support. Major trends in the forecast period include growing use of monoclonal antibodies in ms, preference for high efficacy disease modifying therapies, expansion of outpatient infusion care, improved safety and risk monitoring protocols, rising focus on progressive ms management.

The increasing prevalence of autoimmune disorders is expected to drive the growth of the Tysabri (natalizumab) market in the coming years. Autoimmune disorders occur when the immune system mistakenly attacks the body’s own cells, tissues, or organs, causing inflammation and damage. These conditions can lead to chronic illnesses such as rheumatoid arthritis or multiple sclerosis, with causes involving a combination of genetic and environmental factors. The rise in autoimmune disorders is attributed to genetic predisposition, environmental triggers, and improved awareness and diagnosis, resulting in more cases being identified. Tysabri is effective for autoimmune disorders as it targets specific immune cells, preventing them from causing inflammation and tissue damage, helping manage conditions like multiple sclerosis and Crohn’s disease. For example, in February 2024, Arthritis Australia, a charitable organization advocating for people with arthritis and musculoskeletal conditions, reported that by 2025, around 562,378 Australians are expected to live with rheumatoid arthritis (RA), representing 14% of the total arthritis population. Consequently, the rising prevalence of autoimmune disorders is fueling growth in the Tysabri (natalizumab) market.

The growing focus on personalized medicine is also expected to propel the Tysabri (natalizumab) market forward. Personalized medicine tailors treatments and healthcare strategies to the individual characteristics of each patient, including their genetic profile, environment, and lifestyle, to achieve more effective and precise outcomes. The rise of personalized medicine is driven by advancements in genomic technologies, greater understanding of molecular biology, wider availability of precision diagnostic tools, and demand for targeted therapies that improve patient outcomes while reducing side effects. Tysabri exemplifies personalized medicine by providing a targeted treatment approach for relapsing forms of multiple sclerosis, specifically for patients with certain disease activity and risk profiles, maximizing efficacy while minimizing potential adverse effects. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to six in 2022, including seven drugs tailored for cancer and three for other diseases and conditions. Therefore, the rise of personalized medicine is driving growth in the Tysabri (natalizumab) market.

Key players in the Tysabri (natalizumab) market are focusing on expanding treatment options with alternatives such as biosimilars to provide patients with more effective therapies that enhance quality of life and disease management. Biosimilars to Tysabri offer a cost-effective option for treating highly active relapsing-remitting multiple sclerosis, improving access to essential treatments, especially in underserved areas. For instance, in January 2024, Sandoz Group AG, a Switzerland-based pharmaceutical company, launched Tyruko (natalizumab), the first and only biosimilar to Tysabri, for adults with highly active relapsing-remitting multiple sclerosis (RRMS). This launch strengthens Sandoz’s biosimilar portfolio and aims to increase access to effective and affordable treatments for people living with multiple sclerosis.

Major companies operating in the tysabri (natalizumab) market are Biogen Idec Inc., Sandoz International GmbH, Polpharma Biologics.

North America was the largest region in the tysabri (natalizumab) market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tysabri (natalizumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tysabri (natalizumab) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the tysabri market by increasing costs for monoclonal antibody production inputs, infusion supplies, and cold chain transportation. These cost pressures are most evident in hospital and outpatient infusion centers. North america and europe experience reimbursement sensitivity due to reliance on imported biologics. However, tariffs are encouraging regional biologic manufacturing investments. This is strengthening long-term supply stability and patient access.

The tysabri (natalizumab) market research report is one of a series of new reports that provides tysabri (natalizumab) market statistics, including tysabri (natalizumab) industry global market size, regional shares, competitors with a tysabri (natalizumab) market share, detailed tysabri (natalizumab) market segments, market trends and opportunities, and any further data you may need to thrive in the tysabri (natalizumab) industry. This tysabri (natalizumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Tysabri (natalizumab) is a monoclonal antibody used to treat relapsing multiple sclerosis (MS) and Crohn's disease by reducing inflammation and protecting nerves from damage. It helps decrease the frequency of relapses and slows the progression of physical disability in adults with relapsing forms of MS, including relapsing-remitting MS (RRMS) and active secondary progressive MS (SPMS).

The primary indications for Tysabri (natalizumab) are multiple sclerosis and Crohn's disease. Multiple sclerosis is a condition that causes the deterioration of the protective covering of nerves. Tysabri is used in various patient settings, including inpatient and outpatient care, and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The tysabri market consists of sales of monoclonal antibody therapies, infusion treatments, and immunomodulatory solutions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.